Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt ...

Symptoms are often mistaken for irritation, thrush or an STI, delaying proper treatment. Campaigners say the taboo around ...

An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease ...

CIARA Burnside gave birth to son Ralph but something was immediately wrong – inside her womb the helpless baby’s skin had ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

A medical expert discusses realistic skincare expectations and common misconceptions ...

People with MS are commonly misdiagnosed with other medical conditions, and the reverse is also true. Learn which ...

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 ...

Research shows both disease types may arise from shared inflammatory pathways, genetic susceptibilities, and potential ...

A case report describes a 14-year-old boy whose common cold virus triggered atypical hemolytic uremic syndrome with severe skin necrosis that required surgical debridement after drug therapy failed.

Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug ...

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and ...